Your prediction
Pros and Cons of Advanced Proteome Therapeutics in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Advanced Proteome Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Advanced Proteome Therapeutics | - | - | - | - | - | - | - |
| Northwest Biotherapeutics Inc. | 0.000% | 28.788% | 6.250% | -10.526% | -17.476% | -62.222% | -83.495% |
| Larimar Therapeutics Inc. | -1.120% | 2.326% | -5.376% | 15.789% | 6.024% | 3.529% | -59.070% |
| Achieve Life Sciences Inc. | 0.890% | 3.670% | 10.784% | 158.581% | 52.703% | 17.708% | -9.600% |
News
ABL Ascend Advanced Therapies Names Suman Subramanian as Chief Business Officer
ROCKVILLE, MD /ACCESS Newswire/ August 10, 2026 / ABL Inc and Ascend Advanced Therapiestoday announced the appointment of Suman Subramanian as Chief Business Officer (CBO), further
Lundin Mining Q2 Earnings Call Highlights
Key Points
- Interested in Lundin Mining Co.? Here are five stocks we like better.
- Lundin Mining delivered strong Q2 results, with revenue above $1.2 billion, adjusted EBITDA of $658 million and
Advanced Drainage Systems Q1 Earnings Call Highlights
Key Points
- Interested in Advanced Drainage Systems, Inc.? Here are five stocks we like better.
- Record first-quarter performance: Fiscal 2027 net sales reached $1 billion, up 21% year over